Drugs for B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 250)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ketamine |
Approved, Vet_approved |
Phase 3 |
|
6740-88-1 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
2 |
|
Carmustine |
Approved, Investigational |
Phase 3 |
|
154-93-8 |
2578 |
Synonyms:
1,3-Bis(.beta.-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)nitrosourea
1,3-Bis(beta-chloroethyl)-1-nitrosourea
1,3-BIS(CHLOROETHYL)-1-NITROSOUREA
154-93-8
AC-10563
AC1L1DZQ
AI3-52216
BCNU
BCNU [Chloroethyl nitrosoureas]
Becenum
Becenun
Bi CNU
Bicnu
BiCNU
BiCNU (TN)
Bio-0118
Bis(2-chloroethyl)1-nitrosourea
Bis(2-chloroethyl)nitrosourea
Bis(chloroethyl)nitrosourea
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]
bis-chloroethylnitrosourea
Bischloroethylnitrosourea
Bis-N,N'-(chloroethyl)nitrosourea
BRN 2049744
C 0400
C0400_SIGMA
C5H11Cl2N3O2
Carmubris
Carmustin
Carmustina
Carmustina [INN-Spanish]
carmustine
Carmustine
Carmustine (USAN/INN)
Carmustine [USAN:INN:BAN]
carmustine in ethanol
Carmustinum
Carmustinum [INN-Latin]
CCRIS 810
CHEBI:3423
CHEMBL513
CID2578
D002330
D00254
DB00262
DivK1c_000835
DTI 015
|
EINECS 205-838-2
EU-0100188
FDA 0345
FIVB
FT-0083563
Gliadel
Gliadel Wafer
Gliadel, BCNU, NSC-409962, Becenun, Carmustine
HMS2092J22
HMS502J17
I14-11976
IDI1_000835
KBio1_000835
KBio2_000745
KBio2_003313
KBio2_005881
KBioGR_001296
KBioSS_000745
Lopac0_000188
Lopac-C-0400
LS-890
MLS001333962
MolPort-003-665-505
N,N'-bis(2-chloroethyl)-N-nitrosourea
N,N'-Bis(2-chloroethyl)-N-nitrosourea
N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
NCGC00015204-01
NCGC00015204-02
NCGC00015204-06
NCGC00093665-01
NCGC00093665-02
NCGC00093665-03
NCGC00093665-04
NCI60_003931
NCI-C04773
NINDS_000835
Nitrumon
NSC 409962
NSC409962
NSC-409962
Prestwick_997
S1521_Selleck
SK 27702
SMR000058426
Spectrum_000265
Spectrum4_000888
Spectrum5_000920
SRI 1720
STK624770
UNII-U68WG3173Y
WLN: ONN2GVM2G
ZINC03830387
|
|
3 |
|
Pixantrone |
Approved, Investigational |
Phase 3 |
|
144510-96-3 |
|
Synonyms:
6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione
Pixantrona
|
|
|
4 |
|
Sargramostim |
Approved, Investigational |
Phase 3 |
|
83869-56-1, 123774-72-1 |
|
Synonyms:
123774-72-1
D05803
Leukine
Leukine (TN)
Recombinant human granulocyte-macrophage colony stimulating factor
rGM-CSF
|
rHu GM-CSF
Sargramostim
Sargramostim (genetical recombination)
Sargramostim (genetical recombination) (JAN)
Sargramostim (USAN/INN)
|
|
5 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 441203 84093 |
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatin
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
|
CPDC
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
6 |
|
Allopurinol |
Approved |
Phase 3 |
|
315-30-0 |
2094 |
Synonyms:
1,5-dihydro-4H-pyrazolo(3,4-D)Pyrimidin-4-one
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one
1,5-dihydro-4H-pyrazolo(3,4-D)Pyrimidine-4-one
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
184856-42-6
1H-pyrazolo(3,4-D)Pyrimidin-4-ol
1H-Pyrazolo(3,4-d)pyrimidin-4-ol
22767-92-6
315-30-0
39464-14-7
4-HPP
4H-pyrazolo(3,4-D)Pyrimidin-4-one
4H-Pyrazolo(3,4-d)pyrimidin-4-one
4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine
4-Hydroxy-1H-pyrazolo(3,4-D)pyrimidine
4-Hydroxy-3,4-pyrazolopyrimidine
4-hydroxypyrazolo(3,4-D)Pyrimidine
4-Hydroxypyrazolo(3,4-d)pyrimidine
4'-Hydroxypyrazolol(3,4-d)pyrimidine
4'-Hydroxypyrazolol(3,4-D)pyrimidine
4-Hydroxypyrazolopyrimidine
4-Hydroxypyrazolyl(3,4-d)pyrimidine
4-Hydroxypyrazolyl(3,4-D)pyrimidine
7HP
A 8003
A0907
A8003_SIGMA
AC-019
AC1L1CWL
AC1Q6FWV
AC1Q6GP7
Adenock
Ailural
Ailurial
AKOS000267490
AKOS000269759
AL-100
Allohexal
Allohexan
Alloprin
Allopur
Allo-Puren
Allopurin
allopurinol
Allopurinol
Allopurinol alphapharm brand
Allopurinol amrad brand
Allopurinol aps brand
Allopurinol ashbourne brand
Allopurinol azupharma brand
Allopurinol basf brand
Allopurinol bicther brand
Allopurinol boots brand
Allopurinol clonmel brand
Allopurinol dorsch brand
Allopurinol douglas brand
Allopurinol gepepharm brand
Allopurinol hennig brand
Allopurinol hexal brand
Allopurinol horner brand
Allopurinol icn brand
Allopurinol jenapharm brand
Allopurinol merckle brand
Allopurinol merz brand
Allopurinol multipharma brand
Allopurinol nicholas brand
Allopurinol novopharm brand
Allopurinol pharmafarm brand
Allopurinol pinewood brand
Allopurinol protea brand
Allopurinol r.a.n. brand
Allopurinol rima brand
Allopurinol roche brand
Allopurinol rosen brand
Allopurinol rougier brand
Allopurinol Sodium
Allopurinol tad brand
Allopurinol thiemann brand
Allopurinol wellcome brand
Allopurinol(I)
Allopurinolum
Allopurinolum [INN-Latin]
Allorin
Allozym
Allpargin
Allural
Aloprim
Alopurinol
Alopurinol [INN-Spanish]
Aloral
Alositol
Alphapharm brand OF allopurinol
Aluline
Amrad brand OF allopurinol
Anoprolin
Anzief
Apo-Allopurinol
APS brand OF allopurinol
Apulonga
Apurin
Apurol
Ashbourne brand OF allopurinol
Atisuril
Azupharma brand OF allopurinol
B. W. 56-158
BASF brand OF allopurinol
BB_SC-5394
Bicther brand OF allopurinol
BIM-0061756.0001
Bio-0799
Bleminol
Bloxanth
Boehringer mannheim brand OF allopurinol
Boots brand OF allopurinol
BSPBio_001798
BW 56158
BW 56-158
BW-56-158
Byk gulden brand OF allopurinol
C5H4N4O
Caplenal
Capurate
CCRIS 626
Cellidrin
CHEBI:40279
CHEBI:495607
CHEMBL1467
CID2094
Clonmel brand OF allopurinol
Cosuric
CPD000059083
CPD-9024
D000493
Dabrosin
Dabroson
DB00437
DivK1c_000685
Dorsch brand OF allopurinol
Douglas brand OF allopurinol
Dura Al
EINECS 206-250-9
|
Embarin
EN000932
Epidropal
Epuric
EU-0100102
Fawns and mcallan brand OF allopurinol
Foligan
Geapur
Gepepharm brand OF allopurinol
Gichtex
glaxo Wellcome brand OF allopurinol
Gotax
Hamarin
Hennig brand OF allopurinol
Henning berlin brand OF allopurinol
Hexal brand OF allopurinol
Hexanuret
HMS1920A15
HMS2091G15
HMS502C07
Horner brand OF allopurinol
HPP
HSDB 3004
I03-0052
ICN brand OF allopurinol
IDI1_000685
Jenapharm brand OF allopurinol
Jenapurinol
Jsp005881
KBio1_000685
KBio2_000386
KBio2_002954
KBio2_005522
KBio3_001298
KBioGR_000550
KBioSS_000386
Ketanrift
Ketobun-A
Ledopur
Lopac0_000102
Lopac-A-8003
Lopurin
LS-1180
Lysuron
Merckle brand OF allopurinol
Merz brand OF allopurinol
Milurit
Milurite
Miniplanor
MLS000069453
MLS001148183
MolPort-000-141-383
MolPort-000-870-337
MolPort-004-758-159
MolPort-004-758-166
MolPort-004-758-167
MolPort-004-758-643
Monarch
Multipharma brand OF allopurinol
NCGC00015094-01
NCGC00015094-03
NCGC00015094-06
NCGC00091134-01
NCGC00091134-02
NCGC00091134-03
NCGC00094580-01
NCGC00094580-02
nchembio.92-comp3
nchembio732-comp4
NCIOpen2_001825
Nektrohan
Nicholas brand OF allopurinol
NINDS_000685
Novopharm brand OF allopurinol
Novopurol
NSC 101655
NSC 1390
NSC101655
NSC1390
NSC-1390
Pan quimica
Pan Quimica
Pharmafarm brand OF allopurinol
Pinewood brand OF allopurinol
Prestwick_511
Progout
Protea brand OF allopurinol
Pureduct
Purinol
Quimica, pan
Quimica, Pan
R.A.N. brand OF allopurinol
Reig jofre brand OF allopurinol
Remid
Rhône poulenc rorer brand OF allopurinol
Rhône-poulenc rorer brand OF allopurinol
Riball
Rima brand OF allopurinol
Rimapurinol
Roche brand OF allopurinol
Rosen brand OF allopurinol
Roucol
Rougier brand OF allopurinol
S1630_Selleck
SAM002554884
Sigapurol
SMR000059083
SPBio_000056
Spectrum_000026
SPECTRUM1500108
Spectrum2_000098
Spectrum3_000289
Spectrum4_000135
Spectrum5_000768
STK378584
STK711106
Suspendol
TAD brand OF allopurinol
Takanarumin
Thiemann brand OF allopurinol
Tipuric
UNII-63CZ7GJN5I
Urbol
Uribenz
Uricemil
Uridocid
Uriprim
Uripurinol
Uritas
Urobenyl
Urolit
Urosin
Urtias
Urtias 100
Wellcome brand OF allopurinol
Xanthomax
Xanturat
Xanturic
Zygout
Zyloprim
Zyloric
|
|
7 |
|
Bleomycin |
Approved, Investigational |
Phase 3 |
|
11056-06-7 |
5360373 |
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
Almirall brand OF bleomycin sulfate
Bellon brand OF bleomycin sulfate
Bellon, bléomycine
Blanoxan
Blenoxane
Bleo
bleo Cell
bleo-Cell
BLEOcell
Bleocin
Bleogin
Bleolem
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
bleomycin
Bleomycin
Bleomycin a(2)
Bleomycin A(2)
bleomycin a2
Bleomycin a2
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin b(2)
Bleomycin B(2)
Bleomycin b2
Bleomycin B2
Bleomycin sulfate
|
Bleomycin sulphate
Bleomycine
Bleomycine [INN-French]
Bléomycine bellon
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
Bleomycinum mack
BLM
Bristol myers squibb brand OF bleomycin sulfate
Bristol-myers squibb brand OF bleomycin sulfate
Bull brand OF bleomycin sulfate
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
Cell pharm brand OF bleomycin sulfate
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
Lemery brand OF bleomycin sulfate
LMPK14000006
LS-44860
LS-524
Lundbeck brand OF bleomycin sulfate
Mack brand OF bleomycin sulfate
Mack, bleomycinum
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
Sulfate, bleomycin
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
|
|
8 |
|
Lenograstim |
Approved, Investigational |
Phase 2, Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
9 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 3 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
10 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 3 |
|
83-43-2 |
6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6a-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medric acid
|
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
δ(1)-6a-methylhydrocortisone
δ(1)-6α-methylhydrocortisone
|
|
11 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 3 |
|
2921-57-5 |
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
12 |
|
Prednisolone |
Approved, Vet_approved |
Phase 3 |
|
50-24-8 |
5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-pregnadiene-3,20-dione-11β,17α,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11b,17a,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
Delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
Delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di adreson F
Di Adreson F
Di-adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
Hydeltrone
|
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone acetate
Prednisolone Acetate
Prednisolone sodium phosphate
Prednisolone Sodium Phosphate
Prednisolone tebutate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
δ(1)-dehydrocortisol
δ(1)-dehydrohydrocortisone
δ(1)-hydrocortisone
|
|
13 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 3 |
|
52-21-1 |
|
14 |
|
Vindesine |
Approved, Investigational |
Phase 3 |
|
59917-39-4, 53643-48-4 |
40839 |
Synonyms:
3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
AC1L24KY
C43H55N5O7
CHEBI:36373
CHEMBL219146
CID40839
Compound 112531
D06304
DAVA
DB00309
Desacetylvinblastine amide
Desacetylvinblastine amide sulfate
Desacetylvinblastine Amide Sulfate
EG labo brand OF vindesine sulfate
EINECS 258-682-2
Eldesine
Eldisine
Enison
|
HMS2090E15
HSDB 6961
Lilly 112531
Lilly brand OF vindesine sulfate
LS-162145
methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
MolPort-005-933-570
NSC-245467
STOCK1N-75293
Sulfate, vindesine
UNII-RSA8KO39WH
Vindesin
Vindesina
Vindesina [INN-Spanish]
vindesine
Vindesine
Vindesine (USAN/INN)
Vindesine [USAN:BAN:INN]
Vindesine [USAN:INN:BAN]
Vindesine sulfate
Vindesine Sulfate
Vindesinum
Vindesinum [INN-Latin]
|
|
15 |
|
Levoleucovorin |
Approved, Investigational |
Phase 2, Phase 3 |
|
68538-85-2 |
|
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
ácido levofolínico
|
Citrovorum factor
Levofolene
Levofolinic acid
L-Folinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
|
|
16 |
|
Idarubicin |
Approved |
Phase 3 |
|
58957-92-9 |
42890 |
Synonyms:
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
4 Demethoxydaunorubicin
4 Desmethoxydaunorubicin
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
4-Desmethoxydaunorubicin
4-DMD
57852-57-0
57852-57-0 (HYDROCHLORIDE)
58957-92-9
AC1L28SA
AC1Q6JJ4
BRD-K69650333-001-01-1
C26H27NO9
CCRIS 5083
CHEBI:42068
CHEMBL1117
CID42890
D08062
DB01177
DM5
DMDR
EU-0100600
HMS2089D05
Hydrochloride, idarubicin
I 1656
I06-1097
I1656_SIGMA
Idamycin
|
Idamycin PFS
Idarubicin
IDARUBICIN
Idarubicin (INN)
Idarubicin [INN:BAN]
Idarubicin Aglycone
Idarubicin Hcl
Idarubicin Hcl Pfs
Idarubicin HCl PFS
idarubicin hydrochloride
Idarubicin hydrochloride
Idarubicin Hydrochloride
Idarubicina
Idarubicina [INN-Spanish]
Idarubicine
Idarubicine [INN-French]
Idarubicinum
Idarubicinum [INN-Latin]
IMI 30
IMI30
IMI-30
KBioSS_002388
Lopac0_000600
LS-94015
MLS000759470
NCGC00093976-01
NCGC00093976-02
NCGC00093976-03
NCGC00093976-04
NSC256439
NSC-256439
SMR000466355
UNII-ZRP63D75JW
Zavedos
Zavedos (TN)
|
|
17 |
|
Rasburicase |
Approved, Investigational |
Phase 2, Phase 3 |
|
134774-45-1 |
|
Synonyms:
Elitek
Fasturtec
Rasburicasa
rasburicase
|
Rasburicase
Urate oxidase
Uricase
|
|
18 |
|
Lenalidomide |
Approved |
Phase 3 |
|
191732-72-6 |
216326 |
Synonyms:
191732-72-6
1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-amino-1-Oxoisoindolin-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
346670-73-3
443912-14-9
AC1L50II
AC-914
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CDC 501
CDC-501
CDC-5013
Celgene brand of lenalidomide
Celgene brand OF lenalidomide
CHEMBL848
CID216326
D04687
|
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMiD3
IMiD3 cpd
IMiD3 CPD
IMID-5013
Lenalidomida
lenalidomide
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
LS-184040
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
|
|
19 |
|
ofatumumab |
Approved |
Phase 3 |
|
679818-59-8 |
6918251 |
Synonyms:
Arzerra
HuMax-CD20
HuMax-CD20, 2F2
|
ofatumumab
Ofatumumab
Ofatumumabum
|
|
20 |
|
Ginseng |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
50647-08-0 |
|
Synonyms:
Aralia ginseng root
Asian ginseng root
Chinese ginseng root
Ginseng (panax ginseng)
Ginseng extract
Ginseng, asian
Hong shen root
Insam root
Korean ginseng
Korean ginseng root
Ninjin root
|
Panax ginseng
Panax ginseng root
Panax ginseng root extract
Panax schinseng root
Panax verus root
Red ginseng
Ren seng root
Ren shen
Ren shen root
True ginseng root
|
|
21 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2, Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
22 |
|
Molgramostim |
Investigational |
Phase 3 |
|
99283-10-0 |
|
23 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 3 |
|
2920-86-7 |
|
Synonyms:
(+)-prednisolone hemisuccinate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
Prednisolone hydrogen succinate
Prednisolone succinate
|
|
24 |
|
Anesthetics, General |
|
Phase 3 |
|
|
|
25 |
|
Anesthetics, Intravenous |
|
Phase 3 |
|
|
|
26 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
27 |
|
Anesthetics, Dissociative |
|
Phase 3 |
|
|
|
28 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
29 |
|
Antioxidants |
|
Phase 3 |
|
|
|
30 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
31 |
|
Analgesics, Opioid |
|
Phase 3 |
|
|
|
32 |
|
Vitamin B Complex |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Folate |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Vitamin B9 |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Trace Elements |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Nutrients |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Micronutrients |
|
Phase 2, Phase 3 |
|
|
|
38 |
|
Vitamins |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Methylprednisolone Acetate |
|
Phase 3 |
|
|
|
40 |
|
Adjuvants, Immunologic |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
Antidotes |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Hematinics |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
44 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
45 |
|
Antibodies |
|
Phase 3 |
|
|
|
46 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
47 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
48 |
|
Bendamustine Hydrochloride |
|
Phase 3 |
|
|
|
49 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
50 |
|
Denileukin diftitox |
Approved, Investigational |
Phase 2 |
|
173146-27-5 |
|
Synonyms:
Denileukin
denileukin diftitox
Diphtheria toxin precursor
DT
|
Interleukin-2/diptheria toxin fusion protein
NAD(+--diphthamide ADP- ribosyltransferase)
Ontak
|
|
Interventional clinical trials:
(show top 50)
(show all 301)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients |
Unknown status |
NCT01316744 |
Phase 3 |
ketamine hydrochloride |
2 |
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients |
Unknown status |
NCT03023358 |
Phase 3 |
chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone |
3 |
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) |
Completed |
NCT02747043 |
Phase 3 |
ABP 798;Rituximab |
4 |
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 |
Completed |
NCT00400478 |
Phase 3 |
Rituximab |
5 |
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant |
Completed |
NCT01321541 |
Phase 3 |
Pixantrone + Rituximab;Gemcitabine + Rituximab |
6 |
A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY) |
Completed |
NCT00012051 |
Phase 3 |
carmustine;cisplatin;cytarabine;dexamethasone;etoposide;ifosfamide;melphalan;methotrexate |
7 |
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma |
Completed |
NCT00000658 |
Phase 3 |
Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Sargramostim;Dexamethasone |
8 |
A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma |
Completed |
NCT00719472 |
Phase 3 |
Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs |
9 |
Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) |
Completed |
NCT00750009 |
Phase 3 |
|
10 |
The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study |
Completed |
NCT00719563 |
Phase 3 |
American ginseng |
11 |
Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. |
Completed |
NCT00666211 |
Phase 3 |
|
12 |
Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China |
Recruiting |
NCT02405676 |
Phase 2, Phase 3 |
Prednisone,Vincristine, Cyclophosphamide;Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone;Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone;Rituximab |
13 |
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) |
Recruiting |
NCT03570892 |
Phase 3 |
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT) |
14 |
Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers |
Recruiting |
NCT02991638 |
Phase 3 |
Ibrutinib |
15 |
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents |
Recruiting |
NCT03206671 |
Phase 3 |
Rituximab window;Additional doses of Rituximab;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin hydrochloride;Vindesine Sulfate;Etoposide;Ifosfamide;Methotrexate;Prednisolone;Vincristine |
16 |
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma |
Recruiting |
NCT02703272 |
Phase 3 |
Ibrutinib;Rituximab;Ifosfamide;Carboplatin;Etoposide;Vincristine;Idarubicin;Dexamethasone |
17 |
A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). |
Recruiting |
NCT03575351 |
Phase 3 |
Standard of Care |
18 |
Mature B-Cell Lymphoma And Leukemia Study III |
Recruiting |
NCT01046825 |
Phase 2, Phase 3 |
COPAD;COP, COPD M3, CYM;COP, COPADM8, CYVE |
19 |
A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial |
Recruiting |
NCT02438501 |
Phase 3 |
|
20 |
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial |
Active, not recruiting |
NCT01516580 |
Phase 3 |
Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C |
21 |
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma |
Active, not recruiting |
NCT01996865 |
Phase 3 |
Lenalidomide;Rituximab |
22 |
A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab |
Terminated |
NCT01289223 |
Phase 3 |
Bendamustine IV |
23 |
Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy |
Terminated |
NCT01200589 |
Phase 3 |
|
24 |
SPINOZA / ×©×¤×™× ×•×–×”. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL |
Terminated |
NCT02366663 |
Phase 3 |
Carmustine;Etoposide;Cytarabine;Melphalan |
25 |
Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment |
Terminated |
NCT01077518 |
Phase 3 |
Ofatumumab;Bendamustine infusion;Ofatumumab and Bendamustine infusions (Arm A);Bendamustine infusion (Arm B) |
26 |
Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia |
Unknown status |
NCT02981745 |
Phase 1, Phase 2 |
CT-1530 |
27 |
Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. |
Unknown status |
NCT00385125 |
Phase 2 |
Bendamustine;Rituximab |
28 |
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life |
Unknown status |
NCT00911183 |
Phase 2 |
cyclophosphamide;liposome-encapsulated doxorubicin citrate;prednisone;vincristine sulfate |
29 |
Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen |
Unknown status |
NCT02134262 |
Phase 1, Phase 2 |
Cyclophosphamide or Bendamustine |
30 |
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL |
Unknown status |
NCT01516567 |
Phase 2 |
Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab |
31 |
A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk) |
Unknown status |
NCT00974792 |
Phase 2 |
cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate |
32 |
Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-Line CHOP |
Unknown status |
NCT00022932 |
Phase 2 |
Iodine-131 Anti-B1 Antibody |
33 |
Pilot Study of Autologous T Lymphocytes With Antibody-Dependent Cell Cytotoxicity in Patients With CD20-Positive B-Cell Malignancies |
Unknown status |
NCT02315118 |
Phase 1, Phase 2 |
T-cell therapy + Rituximab + IL-2 |
34 |
Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status |
Unknown status |
NCT00333008 |
Phase 2 |
Doxil;Cyclophosphamide;Vincristine;Prednisone;Rituximab;Pegfilgrastim |
35 |
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL) |
Completed |
NCT02151903 |
Phase 1, Phase 2 |
DI-Leu16-IL2 |
36 |
A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non-Hodgkins Lymphoma. |
Completed |
NCT00211276 |
Phase 2 |
ONTAK (denileukin diftitox) |
37 |
A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma |
Completed |
NCT00166439 |
Phase 2 |
Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) |
38 |
A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia |
Completed |
NCT01030536 |
Phase 1, Phase 2 |
CAT-8015 20 mcg/kg;CAT-8015 30 mcg/kg;CAT-8015 40 mcg/kg;CAT-8015 50 mcg/kg;CAT-8015 60 mcg/kg |
39 |
A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas |
Completed |
NCT00054639 |
Phase 2 |
|
40 |
A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL) |
Completed |
NCT01874288 |
Phase 1, Phase 2 |
0.5 mg/m2 DI-Leu16-IL2;1.0 mg/m2 DI-Leu16-IL2;2.0 mg/m2 DI-Leu16-IL2;4.0 mg/m2 DI-Leu16-IL2;6.0 mg/m2 DI-Leu16-IL2;8.0 mg/m2 DI-Leu16-IL2;10.0 mg/m2 DI-Leu16-IL2;50mg/m2 Rituximab |
41 |
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma |
Completed |
NCT02253992 |
Phase 1, Phase 2 |
|
42 |
A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
Completed |
NCT01281917 |
Phase 2 |
Velcade;Temsirolimus |
43 |
An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy |
Completed |
NCT01647971 |
Phase 1, Phase 2 |
Ublituximab |
44 |
A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma |
Completed |
NCT02910063 |
Phase 2 |
Blinatumomab |
45 |
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma |
Completed |
NCT00765245 |
Phase 2 |
Lenalidomide;Lenalidomide;Rituximab |
46 |
Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma |
Completed |
NCT00764517 |
Phase 2 |
Cladribine;Vorinostat |
47 |
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD) |
Completed |
NCT01058239 |
Phase 2 |
bortezomib;rituximab |
48 |
Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL) |
Completed |
NCT02141451 |
Phase 1, Phase 2 |
Rituximab;INCB7839 |
49 |
Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab |
Completed |
NCT00726700 |
Phase 2 |
cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate |
50 |
A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia |
Completed |
NCT00229619 |
Phase 2 |
Rituximab |
|